Senna

Senna Laxative Tablets

Boots Natural Senna Laxative Tablets

Almus Senna 7.5mg Tablets

Each tablet contains Alexandrian Senna fruit (Cassia senna L. (C. acutifolia Delile) fruit) corresponding to 7.5 mg hydroxyanthracene glycosides, calculated as sennoside B

Tablet

A plain greenish-brown round tablet

For short term relief of occasional constipation.

For oral use only

The maximum daily dose of hydroxyanthracene glycosides is 15 mg. This is equivalent to 2 tablets.

The correct individual dose is the smallest required to produce a comfortable soft-formed motion.

Adults, the elderly and children over 12 years: 2 tablets

Children 6-12 years: 1 tablet

Children under 6 years: Not recommended

The tablets should be taken at bedtime and the dose should be decreased as the bowel habit becomes regular.

Normally it is sufficient to take this product for up to two to three times a week.

Duration of use

Use for more than 1 week requires medical supervision.

If there is no bowel movement after three days a doctor should be consulted.

If symptoms persist during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted.

Hypersensitivity to any of the ingredients.

Cases of intestinal obstructions and stenosis, atony, appendicitis, inflammatory colon diseases (e.g. Crohn's disease, ulcerative colitis) abdominal pain of unknown origin, severe dehydration state with water and electrolyte depletion.

Children under 6 years of age.

Do not exceed the stated dose.

Prolonged use may precipitate the onset of an atonic, non-functioning colon.

Prolonged and excessive use may lead to fluid and electrolyte imbalance and hypokalaemia.

Intestinal loss of fluids may promote dehydration. Symptoms may include thirst and oliguria.

Laxatives do not help in long-term weight loss.

Patients taking cardiac glycosides, antiarrhythmic medicinal products, medicinal products inducing QT-prolongation, diuretics, adrenocorticosteroids or liquorice root, have to consult a doctor before taking senna pods concomitantly.

Like all laxatives, senna pods should not be taken by patients suffering from faecal impaction and undiagnosed acute or persistent gastro-intestinal complaints, e.g. abdominal pain, nausea and vomiting, unless advised by a doctor, because these symptoms can be signs of potential or existing intestinal blockage (ileus).

If laxatives are needed every day the cause of the constipation should be investigated. Long-term use of laxatives should be avoided.

If stimulant laxatives are taken for longer than a brief period of treatment, this may lead to impaired function of the intestine and dependence on laxatives. Senna pod preparations should only be used if a therapeutic effect cannot be achieved by a change of diet or the administration of bulk forming agents.

When administering this product to incontinent adults, pads should be changed more frequently to prevent extended skin contact with faeces.

Patients with kidney disorders should be aware of possible electrolyte imbalance.

If the symptoms persist during the use of the medicinal product, a doctor or a pharmacist should be consulted.

Hypokalaemia (resulting from long-term laxative abuse) potentiates the action of cardiac glycosides and interacts with antiarrhythmic medicinal products, which induce reversion to sinus rhythm (e.g. quinidine) and with medicinal products inducing QT-prolongation. Concomitant use with other medicinal products inducing hypokalaemia (e.g. diuretics, adrenocorticosteroids and liquorice root) may enhance electrolyte imbalance.

Pregnancy

There are no reports of undesirable or damaging effects during pregnancy and on the foetus when used at the recommended dosage schedule.

However, as a consequence of experimental data concerning a genotoxic risk of several anthranoids, e.g. emodin and aloe-emodin, use is not recommended during pregnancy.

Lactation

Use during breastfeeding is not recommended as there are insufficient data on the excretion of metabolites in breast milk.

Small amounts of active metabolites (rhein) are excreted in breast milk. A laxative effect in breast fed babies has not been reported.

Studies on the effects on fertility have not been carried out.

No studies on the effect on the ability to drive and use machines have been performed.

Hypersensitivity reactions (pruritis, urticaria, local or generalized exanthema) may occur.

This product may produce abdominal pain and spasm and passage of liquid stools, in particular in patients with irritable colon. However, these symptoms may also occur generally as a consequence of individual overdose. In such cases dose reduction is necessary.

Chronic use may lead to disorders in water equilibrium and electrolyte metabolism and may result in albuminuria and haematuria. Furthermore, chronic use may cause pigmentation of the intestinal mucosa (pseudomelanosis coli) which usually recedes when the patient stops taking the preparation.

Yellow or red-brown (pH dependent) discolouration of urine by metabolites, which is not clinically significant, may occur during the treatment. The frequency is not known.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

The major symptoms of overdose/abuse are griping pain and severe diarrhoea with consequent losses of fluid and electrolytes, which should be replaced. Diarrhoea may especially cause potassium depletion, which may lead to cardiac disorders and muscular asthenia, particularly where cardiac glycosides, diuretics, adrenocorticosteroids or liquorice root are being taken at the same time.

Treatment should be supportive with generous amounts of fluid. Electrolytes, especially potassium, should be monitored. This is especially important in the elderly.

Chronic ingested overdoses of anthranoid containing medicinal products may lead to toxic hepatitis.

Pharmaco-therapeutic group: contact laxatives

ATC-code: A 06 AB

1, 8-dihydroxyanthracene derivatives possess a laxative effect. The β-O-linked glycosides (sennosides) are not absorbed in the upper gut; they are converted by bacteria of the large intestine into the active metabolite (rhein anthrone).

There are two different mechanisms of action:

1. stimulation of the motility of the large intestine resulting in accelerated colonic transit.

2. influence on secretion processes by two concomitant mechanisms viz. inhibition of absorption of water and electrolytes (Na+, Cl-) into the colonic epithelial cells (antiabsorptive effect) and increase of the leakiness of the tight junctions and stimulation of secretion of water and electrolytes into the lumen of the colon (secretagogue effect) resulting in enhanced concentrations of fluid and electrolytes in the lumen of the colon.

Defaecation takes place after a delay of 8 - 12 hours due to the time taken for transport to the colon and metabolisation into the active compound.

The β-O-linked glycosides (sennosides) are neither absorbed in the upper gut nor split by human digestive enzymes. They are converted by the bacteria of the large intestine into the active metabolite (rhein anthrone). Aglyca are absorbed in the upper gut. Animal experiments with radio-labeled rhein anthrone administered directly into the caecum demonstrated absorption < 10%. In contact with oxygen, rhein anthrone is oxidised into rhein and sennidins, which can be found in the blood, mainly in the form of glucuronides and sulphates. After oral administration of sennosides, 3 - 6% of the metabolites are excreted in urine; some are excreted in bile.

Most of the sennosides (ca. 90%) are excreted in faeces as polymers (polyquinones) together with 2 - 6% of unchanged sennosides, sennidins, rhein anthrone and rhein. In human pharmacokinetic studies with senna pods powder (20 mg sennosides), administered orally for 7 days, a maximum concentration of 100 ng rhein/ml was found in the blood. An accumulation of rhein was not observed. Active metabolites, e.g. rhein, pass in small amounts into breast milk. Animal experiments demonstrated that placental passage of rhein is low.

• R52.1 – Chronic intractable pain
• R52.2 – Other chronic pain
• R52.9 – Unspecified pain

Tricalcium phosphate 118

Magnesium stearate

Maize starch

None known.

Amber glass bottle with unlined polypropylene cap: 18 months

Amber glass bottle with polypropylene cap with IHS liner faced with surlyn/aluminium or polyethylene/aluminium: 24 months

HDPE bottle with polypropylene cap with IHS liner faced with either surlyn/aluminium or polyethylene/aluminium: 24 months

HDPE bottle with polypropylene cap with waxed aluminium faced liner: 24 months

PVC/PVDC/aluminium foil blister: 36 months

Glass bottle: Do not store above 25°C. Store in original package.

Blister: Do not store above 25°C. Store in original package.

PET: None

1. Amber glass bottle, unlined polypropylene cap

Pack size: 50, 100, 200

2. Amber glass bottle, polypropylene cap with IHS liner faced with surlyn/aluminium or polyethylene/aluminium.

Pack size: 50, 100, 200

3. HDPE bottle with polypropylene cap with IHS liner faced with surlyn/aluminium or polyethylene/aluminium.

Pack size: 50, 100, 200

4. HDPE bottle with polypropylene cap with waxed aluminium faced liner.

Pack size: 50, 100, 200

5. PVC/PVDC aluminium foil blister.

Pack size: 10, 20, 30, 40, 50, 60, 70, 80, 90, 100

Not applicable.

The Boots Company PLC

1 Thane Road West

Nottingham NG2 3AA

Trading as: BCM

PL 00014/5375R

Date of grant: 29 August 1984

Date of renewal: 25 September 1996

June 2015

• R52.1 – Chronic intractable pain
• R52.2 – Other chronic pain
• R52.9 – Unspecified pain

• R52.1 – Chronic intractable pain
• R52.2 – Other chronic pain
• R52.9 – Unspecified pain